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Abstract
Background: Lipid abnormalities, enhanced inflammation and oxidative stress seem to represent a vicious circle in
atherogenesis, and therapeutic options directed against these processes seems like a reasonable approach in the
management of atherosclerotic disorders. Krill oil (RIMFROST Sublime®) is a phospholipid-rich oil with eicosapentaenoic
acid (EPA): docosahexaenoic acid (DHA) ratio of 1.8:1. In this pilot study we determined if krill oil could favourable affect
plasma lipid parameters and parameters involved in the initiation and progression of atherosclerosis.
Methods: The study was conducted as a 28 days intervention study examining effect-parameters of dietary
supplementation with krill oil (832.5 mg EPA and DHA per day). 17 healthy volunteers in the age group 18–36
(mean age 23 ± 4 years) participated. Plasma lipids, lipoprotein particle sizes, fatty acid composition in plasma
and red blood cells (RBCs), plasma cytokines, antioxidant capacity, acylcarntines, carnitine, choline, betaine, and
trimethylamine-N-oxide (TMAO) were measured before and after supplementation.
Results: Plasma triacylglycerol (TAG) and large very-low density lipoprotein (VLDL) & chylomicron particle
concentrations decreased after 28 days of krill oil intake. A significant reduction in the TAG/HDL cholesterol
resulted. Krill oil supplementation decreased n-6/n-3 polyunsaturated fatty acids (PUFA) ratio both in plasma
and RBCs. This was due to increased EPA, DHA and docosapentaenoic acid (DPA) and reduced amount of
arachidonic acid (AA). The increase of n-3 fatty acids and wt % of EPA and DHA in RBC was of smaller magnitude than
found in plasma. Krill oil intake increased the antioxidant capacity, double bond index (DBI) and the fatty acid
anti-inflammatory index. The plasma atherogenicity index remained constant whereas the thrombogenicity index
decreased. Plasma choline, betaine and the carnitine precursor, γ-butyrobetaine were increased after krill oil
supplementation whereas the TMAO and carnitine concentrations remained unchanged.
Conclusion: Krill oil consumption is considered health beneficial as it decreases cardiovascular disease risk
parameters through effects on plasma TAGs, lipoprotein particles, fatty acid profile, redox status and possible
inflammation. Noteworthy, no adverse effects on plasma levels of TMAO and carnitine were found.
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Background
Cardiovascular disease (CVD) is the leading cause of
death worldwide [1]. Plasma lipids, especially cholesterol
and triacylglycerol (TAG), are associated with risk for
CVD and coronary artery disease [2–4]. Cholesterol is
mostly transported in plasma by specific cholesterol-rich
lipoproteins as low-density lipoproteins (LDL) or high-
density lipoproteins (HDL). TAG is carried in very low-
density lipoproteins (VLDL) and chylomicrons (CMs)
Human trials have shown that plasma concentrations of
high LDL-cholesterol, low HDL-cholesterol and high
TAG are associated with elevated CVD risk [5, 6]. Re-
cently, it has been found that TAG-rich lipoproteins
causally influence risk for coronary artery disease (CAD)
[7]. Moreover, small dense LDL particles are shown to
be more atherogenic than the larger and less dense LDL
particles [8]. Much research has been performed to the
study of various interventions for the prevention of
CVD. Since 1970, regular consumption of fatty fish or
fish oils has been stated to have several positive effects
on CVD because of the presence of n-3 fatty acids,
namely EPA (C20:5n-3) and DHA (C22:6n-3), and lately
docosapentanenoic acid (DPA, C22:5n-3) has also be-
come a focus of interest [9, 10]. Indeed, EPA and DHA
supplementations have been shown to consistently lower
plasma TAG concentration [11, 12] although the efficacy
of EPA and DHA in the prevention of CVD has been
challenged in the recent meta-analyses [13–15]. Thus,
clinical cardiovascular benefits of these n-3 fatty acids
have been reported in several, but not all human trials.
Most probably EPA and/or DHA do not affect CVD
through a single factor, but rather due to several factors
such as plasma lipid concentration [11, 12], systemic and
local inflammation [16], vascular endothelial function
[17, 18], and oxidative stress [17, 18].
Krill oil from Antarctic krill (Euphausia superba) has in
the last years emerged on the market as an alternative
source of EPA and DHA. An increasing number of studies
with krill oil demonstrate health benefits in animals as well
as in humans [19–22]. While fish oils have their bioactive
n-3 fatty acids incorporated into TAG or ethylesters, krill
oil has EPA and DHA esterified in phospholipids (PLs) in
particular phosphatidylcholine (PC). Furthermore, the polar
structure of PLs was shown to increase the bioavailability of
EPA and DHA from krill oil in comparison to fish oil [23].
In addition to its high content of PLs, krill oil contains the
antioxidant astaxanthin, which might enhance stability of
n-3 fatty acids and preserve them from lipid oxidation.
Trimethylamine-N-oxide (TMAO) is a diet and
microbiota-dependent proatherogenic metabolite and a
proposed cardiovascular risk marker [24–26]. It´s precur-
sors are betaine, choline and carnitine [24, 27], thus a high
intake of PC and choline could potentially influence plasma
levels of TMAO.
The main objective of this pilot study was to investi-
gate the effect of krill oil on plasma lipids, lipoprotein
particle concentrations and fatty acid profile in plasma
and red blood cells (RBC). In addition, the effect of krill
oil on inflammation, antioxidant capacity (AOC), and
changes in plasma levels of TMAO was evaluated.
Results
Baseline characteristics of the study participants
The study included 18 healthy volunteers, of which all
completed the supplementation period. One volunteer
had a major protocol deviation, and was excluded. Thus,
17 healthy individuals (15 females, 2 males) were in-
cluded in the final analysis. The mean age was
23 years (range 20–33) and the BMI 20.9 kg/m2
(range 17.6-25.5) (data not shown). Compliance of the
intervention was >95 % for all subjects during the
period (mean 100 %; range 96 % to 100 %).
Safety parameters
No significant adverse effects or other complications were
reported throughout the study. All safety parameters
remained within normal limits both for males and females,
and krill oil supplementation did not change these clinical
parameters compared to baseline, with the exception of a
small increase in gamma-glutamyltransferase (Table 1).
Effect on plasma lipids and lipoprotein particle size
After krill oil supplementation the plasma level of
TAG decreased significantly compared to baseline
(12 %, p = 0.016; Fig. 1a). The total VLDL & CM
particle concentration tended to decrease (p = 0.06)
and this was due to significantly decreased concentra-
tions of large VLDL & CM particles, and partly due to
medium VLDL particle concentration (p = 0.07; Table 2).
Table 1 Effect of krill oil supplementation on safety parameters
Baseline Endpoint p-value
CRP, mg/L 1.5 ± 2.1 2.0 ± 4.3 0.6
ALT, U/L 19.4 ± 6.4 20.0 ± 8.4 0.7
AST, U/L 25.6 ± 5.4 26.6 ± 6.7 0.2
ALP, U/L 61.7 ± 18.6 61.8 ± 16.0 0.8
Bilirubin, μmol/L 6.9 ± 1.9 8.4 ± 4.9 0.2
Protein, g/L 71.5 ± 4.7 71.1 ± 4.2 0.4
Albumin, g/L 46.9 ± 2.4 46.6 ± 2.3 0.5
GT, U/L 12.9 ± 4.7 14.0 ± 5.2 0.04
Insulin, μU/mL 6.3 ± 2.5 6.6 ± 3.7 0.9
Glucose, mmol/L 4.7 ± 0.4 4.8 ± 0.4 0.1
Values are given as means ± standard deviation (n = 17). P-values ≤ 0.05 were
considered statistically significant
Abbreviations: ALT alanine-aminotransferase, ALP alkaline phosphatase,
AST asparat aminotransferase, CRP C-reactive protein,
GT gamma-glutamyltransferase
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A close positive correlation was observed between plasma
TAG and large VLDL & CM and medium VLDL particles
(R/rs = 0.532, p = 0.001 and R = 0.559, p = 0.001, respect-
ively; Fig. 1b and c). Total plasma level of cholesterol
showed a small (4 %) but significant increase by krill oil
supplementation (Fig. 1d). Interestingly, the HDL-
cholesterol (Fig. 1e) and LDL-cholesterol (Fig. 1f ) were
increased by krill oil intake whereas plasma non-HDL-
cholesterol was unchanged (p = 0.07; Fig. 1g). The ratio of
HDL-cholesterol to LDL-cholesterol remained un-
changed after krill oil intake (Fig. 1h). These findings
were accompanied by increased total HDL and LDL
particle concentration mediated by large particle size
(Table 2). Noteworthy, the small LDL particle concen-
tration and the IDL particle concentration remained
unchanged by krill oil supplementation (Table 2). Fi-
nally, the alterations in plasma lipids resulted in a sig-



























































































































































































































































































Fig. 1 Plasma lipid profile after krill oil intake. Plasma TAG (a), correlation between plasma TAG and large VLDL & CM concentration (b), correlation
between plasma TAG and medium VLDL & CM concentration (c), plasma total cholesterol (d), plasma HDL-cholesterol (e), plasma LDL-cholesterol
(f), plasma non-HDL-cholesterol (g), plasma HDL-cholesterol/LDL-cholesterol ratio (h), plasma TAG/HDL-cholesterol (i), plasma total cholesterol/HDL-
cholesterol (j), plasma PL (k), plasma NEFA (l). Values from all 17 participants are shown. Significant difference
was determined by Wilcoxon signed-rank test (*p < 0.05, **p < 0.01). Correlation coefficients (R) were determined by Spearman correlation, and linear
regressions are shown
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(Fig. 1i), while the total cholesterol/HDL cholesterol ratio
was unchanged (Fig. 1j). The plasma PL level increased
significantly (Fig. 1k), while the plasma non-esterified
fatty acid (NEFA) content remained unchanged by krill
oil intake (Fig. 1l).
Fatty acid composition in plasma and RBC
When analysing the effects of krill oil on fatty acid com-
position in plasma and RBC, several findings were re-
vealed. First, while the wt % of monounsaturated fatty
acids (MUFAs) and n-6 fatty acids was decreased both
in plasma and RBC, the wt % of polyunsaturated fatty
acids (PUFAs) was increased due to increased n-3 fatty
acids (Table 3). Total saturated fatty acids (SFAs) were
unchanged by krill oil supplementation. Second, the in-
crease of n-3 fatty acids was reflected by an increase of
EPA (plasma, 218 fold; RBC, 100 fold), DPA (plasma, 50
fold; RBC, 10 fold) and DHA (plasma, 23 fold; RBC, 5
fold). Alpha linolenic acid (ALA, C18:3n-3) was not
changed in plasma and RBC. Third, the 5 % reduction
Table 2 Effect of krill oil supplementation on plasma lipoprotein concentrations
VLDL particle concentration, nmol/L Baseline End of study p-value
Total VLDL & Chylomicron 32.8 ± 22.4 28.1 ± 18.8 0.06
Large VLDL & Chylomicron 1.3 ± 1.0 1.0 ± 0.6 0.04
Medium 11.1 ± 10.4 8.9 ± 8.7 0.07
Small 20.4 ± 12.9 18.3 ± 14.0 0.2
LDL particle concentration, nmol/L
Total 873.6 ± 288.9 943.4 ± 352.8 0.04
Large 447.8 ± 201.5 528.5 ± 218.4 0.04
Small 352.1 ± 230.0 348.5 ± 260.8 0.7
IDL 73.7 ± 43.2 66.4 ± 76.4 0.4
HDL particle concentration, μmol/L
Total 32.1 ± 5.6 33.4 ± 5.7 0.03
Large 8.7 ± 2.8 9.8 ± 3.6 0.04
Medium 10.4 ± 5.6 10.1 ± 5.7 1.0
Small 13.0 ± 3.5 13.5 ± 4.3 0.9
Values are given as means ± standard deviation (n = 17). P-values ≤ 0.05 were considered statistically significant
Abbreviations: HDL high-density lipoprotein, IDL intermediate-density lipoprotein, LDL low-density lipoprotein, VLDL very low-density lipoprotein
Table 3 Effect of krill oil on plasma and red blood cell (RBC) fatty acid profile
Plasma RBC
Fatty acids Wt % Baseline End of study p-value Baseline End of study p-value
SFA 31.8 ± 0.7 31.6 ± 1.0 0.2 40.9 ± 0.6 40.7 ± 0.6 0.8
MUFA 25.2 ± 2.3 23.6 ± 2.9 0.007 17.5 ± 0.7 17.3 ± 0.9 0.02
PUFA 42.8 ± 2.7 44.6 ± 3.2 0.005 41.4 ± 0.7 41.8 ± 0.8 0.003
n-6 PUFAs 37.0 ± 2.7 35.1 ± 3.7 0.008 29.9 ± 1.8 28.5 ± 1.7 <0.0001
C18:2n-6 (LA) 27.7 ± 2.7 26.8 ± 3.5 0.7 9.1 ± 1.0 8.7 ± 1.0 0.02
C20:3n-6 1.5 ± 0.3 1.3 ± 0.3 0.0008 1.5 ± 0.4 1.4 ± 0.3 0.002
C20:4n-6 (AA) 7.0 ± 1.6 6.3 ± 1.4 0.0007 15.9 ± 1.5 15.1 ± 1.4 <0.0001
C22:5n-6 0.1 ± 0.03 0.1 ± 0.02 <0.0001 0.4 ± 0.1 0.4 ± 0.07 <0.0001
n-3 PUFAs 5.7 ± 1.5 9.4 ± 1.6 <0.0001 11.3 ± 1.7 13.2 ± 1.5 <0.0001
C18:3n-3 (ALA) 0.7 ± 0.2 0.7 ± 0.3 0.8 0.2 ± 0.03 0.2 ± 0.04 0.8
C20:5n-3 (EPA) 1.1 ± 0.6 3.6 ± 0.8 0.0002 1.2 ± 0.4 2.5 ± 0.4 <0.0001
C22:5n-3 (DPA) 0.6 ± 0.1 0.8 ± 0.2 <0.0001 2.8 ± 0.4 3.1 ± 0.3 <0.0001
C22:6n-3 (DHA) 3.2 ± 0.8 3.9 ± 0.7 0.0002 7.0 ± 1.2 7.4 ± 1.0 <0.0001
Values indicate plasma and RBC content by percent weight (wt %)
P-values ≤ 0.05 were considered statistically significant
Abbreviations: AA arachidonic acid, ALA alpha linolenic acid, DHA docosahexaenoic acid, DPA docosapentaenoic acid, EPA eicosapentaenoic acid, LA linoleic acid,
MUFAs monounsaturated fatty acids, n-3 omega-3, n-6 omega-6, PUFAs polyunsaturated fatty acids, SFAs saturated fatty acids
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in n-6 fatty acids in plasma and RBC was primarily
reflected by a decrease in the content of linoleic acid
(LA, C18:2n-6) and AA (C20:4n-6; Table 3). Finally,
krill oil supplementation decreased the n-6 to n-3 ratio
(Fig. 2a, b) and increased wt % of EPA and DHA (often
called omega-3 index in RBC), the double bond index
(DBI), and the fatty acid inflammatory index in
both plasma and RBC (Fig. 2c-h). Noteworthy, a more
pronounced effect was observed on the n-6 to n-3 ra-
tio and the fatty acid inflammatory index in plasma com-
pared to RBC, despite a close correlation between wt % of
EPA and DHA in plasma and RBC (R =0.665, p = 0.0001;
data not shown). It is reported that the EPA level in fish
oil is responsible for lowering plasma TAG in animals
[28–30]. However, neither plasma EPA and DHA alone
correlated with plasma TAG and VLDL & CM particle
concentration (data not shown). Moreover, no associations
between the wt % of EPA and DHA in plasma and RBC
were found with plasma TAG. It was of interest, however,
to observe that krill oil supplementation decreased the
plasma thrombogenicity index (Fig. 2i) whereas the ather-
ogenicity index was unchanged (Fig. 2j).
Effect on antioxidant status
Oxidative stress is associated with decreased fatty acid
unsaturation and increased lipid peroxidation [31]. The
plasma total antioxidant capacity (AOC) significantly
increased after krill oil intake (Fig. 3a) and it was of
interest that AOC positively correlated to plasma EPA
concentration (R = 0.395, p = 0.021; Fig. 3b), RBC EPA
concentration (R = 0.443, p = 0.009: Fig. 3c) and RBC
DBI (R = 0.409, p = 0.016; Fig. 3d). No correlation was
found between AOC and DHA concentrations in
plasma and RBC after krill oil intake, but the wt % of
EPA and DHA both in plasma and RBC correlated to
AOC (data not shown).
Effect on systemic inflammation
Krill oil supplementation in humans could be expected
to have anti-inflammatory potential in plasma as the
fatty acid anti-inflammatory index increased (Fig. 2g).
However, the plasma cytokines IL-1β, IL-10, IL-17, gran-
ulocyte colony-stimulating factor (G- CSF) and tumor
necrosis factor alpha (TNFα) were unchanged after krill
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Fig. 2 Fatty acid composition in plasma and RBC after krill oil supplementation. Plasma n-6/n-3 ratio (a), RBC n-6/n-3 ratio (b), plasma wt % of
EPA + DHA (c), RBC wt % of EPA + DHA (omega-3 index)(d), plasma double bond index (e), RBC double bond index (f), plasma anti-inflammatory
index (g), RBC anti-inflammatory index (h), plasma trombogenicity index (i), plasma atherogenicity index (j). Values are given as means with standard
deviations (n= 17). Significant difference was determined by Wilcoxon signed-rank test (***p < 0.001)
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Effect on choline, betaine, carnitine and TMAO
TMAO is a substance formed in the liver from trimethy-
lamine generated by the gut microbiota from dietary PC,
choline, betaine and carnitine [24–27]. Krill contains
both PC and TMAO, while krill oil only contains PC.
The plasma level of TMAO was not affected by krill oil
intake (Fig. 4a). Both choline and its metabolite betaine
increased in plasma after 28 days with krill oil supple-
mentation (Fig. 4b, c), whereas the plasma carnitine level
remained constant (Fig. 4d). The carnitine precursor,
γ-butyrobetaine was significantly increased in plasma
by krill oil intake compared to baseline values (Fig. 4e).
The other carnitine precursor, trimethyllysine, remained
unchanged over the intervention period (Fig. 4f).
Effect on plasma acylcarnitine level
It is reported that high serum concentrations of long-and
medium plasma acylcarnitines are linked to increased risk
of disease progression with CAD, especially in heart failure
patients [32]. Moreover, increased plasma concentrations
of these acylcarnitines may indicate defects in mitochon-
dria function [33]. In the present study, plasma octanoyl-
carnitine level was decreased after krill oil intake (Fig. 5a),
whereas the palmitoylcarnitine and acetylcarnitine levels
remained unchanged (Fig. 5b, c). In the current study a 15
to 20% (compared to baseline) reduction resulted for the
short-chain acylcarnitines, namely iso-/L-valerylcarnitine
and propionylcarnitine (Fig. 5d, e).
Discussion
The present study has shown that 28 days supplementa-
tion of krill oil had significant biological effects in
healthy subjects. Moreover, intake of this EPA-and DHA
rich PC-oil beneficially affected several parameters
linked to CVD-risk, including plasma lipids, lipoprotein
particle concentrations, fatty acid composition, redox
status and potentially inflammation and thrombogen-
icity. However, a small increase in cholesterol was ob-
served. The krill oil intake did not change the safety
parameters (Table 1).
Krill oil intake reduced plasma TAG levels due to de-
creased concentration of large VLDL & CM particles
(Table 2), concomitant with increased concentration of
large HDL particles and decreased TAG/HDL ratio (Fig. 1i).
Large LDL particles also increased after 28 days krill oil
supplementation and this resulted in a modest, but signifi-
cantly higher plasma total cholesterol level (Fig.1d). How-
ever, total cholesterol/HDL, a robust risk parameter in
European populations [34], was unaltered (Fig. 1j). The in-
crease in large HDL particles in response to n-3 PUFA sup-
plementation has been demonstrated in several studies [35,
36], and may be explained by a reduced exposure to choles-
terol ester transfer protein (CETP)-mediated transfer of
cholesterol from HDL particles due to a lower concentra-
tion of TAG rich large VLDL and CM. Interestingly, the in-
creased concentration of large HDL-and LDL particles has
mainly been found with DHA, but not EPA supplementa-
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Fig. 3 Antioxidant capacity (AOC) status after krill oil intake. Plasma level of AOC (a), correlation between plasma EPA concentration and AOC (b),
correlation between EPA concentration in RBC and AOC (c), correlation between DBI and AOC in RBC (d). AOC is given as mean with standard
deviation (n = 14). Significant difference was determined by Wilcoxon signed-rank test (**p < 0.01). Correlation coefficients (R) were determined by
Spearman correlation, and linear regressions are shown
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atherogenic small LDL particles remained constant after
krill oil supplementation.
It has been assumed that EPA or DHA, or both, are
responsible for the TAG-lowering effect after supplemen-
tation of n-3 PUFA. Most studies have used fish oil with
various contents of EPA and DHA, and only a few studies
have examined the effect of EPA and DHA separately to
determine for the effects for each fatty acid. Previous stud-
ies have demonstrated n-3 PUFA supplementation to
lower plasma TAG levels when ingesting 2–4 g EPA and
DHA per day for 6 weeks or longer, although the effect
seem to be strongest among people with an unfavourable
risk profile [11, 12, 39]. Supplementation with 4 g EPA per
day for 6–7 weeks has been shown to reduce TAG by
21 % [40] and 23 % [38] in mildly hyperlipidaemic
subjects, and by 12 % in healthy subjects [41]. The present
study showed a reduction in TAG levels (12 %, p = 0.02) in
healthy young adults after 28 days of supplementation
with 832.5 mg EPA and DHA from krill oil with an
EPA:DHA ratio of approximately 1.8:1. This indicates a
high bioavailability of krill oil (RIMFROST Sublime®)
and a subsequent rapid effect on lipid metabolism.
Moreover, this is in line with a recent study in adults
with high TAG levels where a dose of 0.5-2 g/day krill oil
significantly reduced plasma TAG [20].
In humans, supplementation of EPA gives rise to EPA
and DPA, but not DHA whereas DHA supplementation
gives formation of DPA and EPA [41, 42]. In keeping
with these findings our present study gave rise in DPA
both in RBC (approximately 10 %) and plasma (approxi-
mately 23 %) and was greater than would be expected,
as krill oil does not contain DPA (Table 4). Previous
studies have shown similar results, both in RBC [43] and
in plasma [21, 44, 45]. Moreover, in the present study
the increase in DPA both in plasma and RBCs was
higher than DHA. We have recently found that PLs
from herring roe with a DHA:EPA ratio of about 3:1 de-
creased plasma TAG in healthy subjects [46]. Despite a
dose of 132 mg DPA/day and the possibility of formation
of DPA from EPA, DPA levels were not influenced by
herring roe PLs. This suggests that DPA is less import-
ant in mediating TAG lowering effects both in krill oil
and oil from herring.
Studies in cultured rat hepatocytes have shown that
EPA increases mitochondrial fatty acid oxidation [30],
and as recently reviewed, plasma acylcarnitine levels can
give an indication on mitochondrial function [33]. When
acyl-CoAs accumulate in the mitochondrial matrix, acyl-
carnitine formation is favoured, which can exit the mito-










































































































Fig. 4 Plasma TMAO, carnitine, and carnitine precursors after krill oil intake. Plasma levels of TMAO (a), choline (b), betaine (c), carnitine (d),
γ-butyrobetaine (e), and trimethyllysine (f). Values are given as means with standard deviation (n = 17). Significant difference was determined
by Wilcoxon signed-rank test (*p < 0.05, **p < 0.01, ***p < 0.001)
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intra-mitochondrial relationship between acyl-CoA and
free CoA is reflected by the extra-mitochondrial acyl-
carnitine to free carnitine ratio, given that any mitochon-
drial acyl-CoA accumulation leads to a corresponding
increase in acylcarnitines. In situations of inefficient
β-oxidation, intermediates such as octanoyl- and pal-
mitoylcarnitine will be formed, which are considered
toxic [47]. Elevated palmitoylcarnitine has been asso-
ciated with poor prognosis in chronic heart failure
(CHF) patients [32]. In the present study the plasma
level of octanoylcarnitine was decreased by krill oil
supplementation. Altogether, this suggests that the
krill oil intervention may be responsible for more ef-
ficient fatty acid oxidation of medium-chain length
fatty acids. Noteworthy, this is in consistence with
findings in animal studies where krill oil was shown
to influence metabolic pathways, including fatty acid
oxidation, lipid biosynthesis and acylcarntine turn-
over [48, 49].
Choline is mainly utilized for PC biosynthesis, which
is required for membrane formation and can take
place through two pathways, namely CDP-choline
(Kennedy) pathway and the phospatidylethanolamine
N-methyltransferase (PEMT) pathway. Moreover,
choline can be oxidized to betaine, which is involved
in the remethylation of homocysteine to methionine
in the one-carbon cycle [50]. In the present study
plasma choline and betaine was increased by krill sup-
plementation, indicating an increased PC degradation
and increased choline oxidation, respectively. Choline
is an important nutrient and is predominantly ob-
tained from the diet [51, 52], although it can be syn-
thesised de novo. In a recent European study, the
average choline intake was below the adequate intake
(set by the Institute of Medicine in the USA) in most
of the population groups considered [53]. Thus, krill
oil can be a well-suited supplement for populations
vulnerable to choline deficiency.
TMAO is formed in the liver from trimethylamine, a
product generated by the gut microbiota from dietary
PC, choline and carnitine. Trimethylamine can also be
generated from betaine [26]. Recent studies have
shown that TMAO is a diet and microbiota-dependent
proatherogenic metabolite and cardiovascular risk
marker [24–27]. Interestingly, in the present study the
plasma TMAO level remained constant by krill oil
supplementation, demonstrating that the extra choline

























































































Fig. 5 Plasma acylcarnitines after krill oil intake. Plasma levels of octanoylcarnitine (a), palmitoylcarnitine (b), acetylcarnitine (c), iso-/L-valerylcarnitine (d),
and propionylcarnitine (e). Values are given as means with standard deviation (n= 17). Significant difference was determined by Wilcoxon signed-rank
test (**p < 0.01, ***p < 0.001)
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AA is a precursor for prostaglandins [16] and is con-
sidered proinflammatory. Krill oil supplementation de-
creased the level of AA and increased amounts of n-3
PUFAs in plasma and RBC resulting in an increased
anti-inflammatory fatty acid index. This implies that krill
oil intake has anti-inflammatory properties. The plasma
cytokines, however, remained unchanged. The plasma
total antioxidant status significantly increased after krill
oil supplementation (Fig. 3a) and it was of interest that
AOC positively correlated with the plasma and RBC
levels of EPA and wt % of EPA and DHA. Moreover,
plasma AOC correlated with RBC DBI but no correl-
ation was found between AOC and DHA concentrations
in plasma and RBC after krill oil intake (data not
shown). Whether the presence of astaxanthin is respon-
sible for the oxidative protective effect observed, should
be considered [54]. This is an important point, as the re-
moval of protective trace compounds in the generation
of highly purified PUFAs has been reported to reduce
the beneficial effect of fish oil supplements [55].
Conclusions
28 days of krill oil supplementation in healthy young
adults reduced plasma TAG and large VLDL & CM par-
ticle concentration, whereas the concentrations of large
HDL and LDL were increased. The changes in fatty acid
composition in plasma and RBC were accompanied by
increased n-3 PUFAs, decreased level of AA and in-
creased the plasma antioxidant status. Furthermore, no
adverse effects of krill oil intake on plasma TMAO levels
were found. Thus, a dose of 832.5 mg EPA and DHA
from krill oil had beneficial biological effects in persons
with a normal lipid profile, and may prevent the devel-
opment of several risk factors related to CVD.
Methods
Study population
18 subjects in the age group 18–36, with a body mass
index (BMI; in kg/m2) of 17–29.9 and in a generally
good health, were recruited to the pilot study. Exclusion
criteria were disease related to fat metabolism or diges-
tion, acute or chronic inflammatory conditions, liver dys-
functions, pregnancy (all self-reported), obesity (defined as
a BMI ≥30), inability to swallow capsules and unwilling-
ness to take blood samples.
Intervention
The intervention used was krill oil capsules (RIMFROST
Sublime ®, Rimfrost AS, Fosnavaag, Norway). The lipid-
and fatty acid composition of the oil is presented in
Table 4. Each capsule (500 mg) contained 210 mg PLs
and 120 mg n-3 PUFA, of which 60 mg was EPA and
32.5 mg DHA. The participants received 9 capsules per
day for 28 days, corresponding to a daily dose of
832.5 mg EPA and DHA Moreover, the oil contained
192 mg astaxanthin per kg.
Table 4 Composition of the krill oil (wt %)
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Abbreviations: see legend to Table 3
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Study procedures
Subjects were recruited through advertisements presented
at the University of Bergen and the Bergen University
College (Norway). After written informed consent to par-
ticipate was provided, blood samples were drawn, and body
weight and height were recorded to calculate body mass
index (BMI; kg/m2). Study participants were interviewed
about their dietary intake of food stuffs rich in n-3 fatty
acids and PLs, focusing on the amount and frequency of
the last month intake. Participants were advised to maintain
a steady intake of these food items during the study period,
refrain from the use of all nutritional supplements, and to
maintain their body weight. At the end of the study, all par-
ticipants were asked to answer questionnaires to assess self-
reported compliance and product tolerance. The 18 sub-
jects included all completed the intervention period. How-
ever, one subject (male) was excluded from the final
analysis due to protocol deviation revealed by the
questionnaires.
Blood sample collection
Blood samples were collected from subjects fasted over-
night and seated for 15 minutes, at the beginning (base-
line) and end of the study. At both time points, blood
samples were centrifuged and EDTA-plasma and serum
was collected after a minimum of 15 minutes and max-
imum of 30 minutes at room temperature. Blood sam-
ples for isolation of RBC was drawn in EDTA-tubes,
centrifuged at 3000 rpm for 10 minutes, and plasma and
interface removed. RBC was then washed three times in
phosphate buffered saline (PBS), with subsequent centri-
fugation and removal of the buffy coat (white blood
cells) between each wash. Finally, the original volume
was reconstituted using PBS. All samples were aliquoted
and stored at −80°C for further analysis.
Total fatty acid composition in the red blood cells (RBC)
and in plasma
The total fatty acid composition was analysed in RBC
and in EDTA-plasma, as previously described [56].
The omega-3 index is defined as the sum of EPA and
DHA in RBC, expressed as a percentage of the total fatty
acid (TFA) content. The anti-inflammatory index is de-
fined as the sum of EPA (C20:5n-3), dihomo-gamma-
linolenic acid (DGLA, C20:3n-6), DHA (C22:6n-3) and
DPA (C22:5n-3), divided on AA (C20:4n-6), multiplied
with 100. The double bound index (DBI) is defined as
(MUFA + 2*(C18:2n6 + C20:2n6 + C22:2n6) + 3*(C18:3n6
+ C18:3n3 + C20:3n9 + C20:3n6) + 4*(C18:4n3 + C20:4n6
+ C20:4n3 + C22:4n6) + 5*(C20:5n3 + C21:5n3 + C22:5n6
+ C22:5n3) + 6*(C22:6n3))/TFA. The atherogenicity index
(AI) and the thrombogenenicity (TI) were deter-
mined according to Ulbricht and Southgate [57]
equations: AI = (C12:0 + 4*C14:0 + C16:0)/(ΣMUFA
+ Σ(n-6 PUFA) + Σ(n-3 PUFA)). TI = (C14:0 + C16:0 +
C18:0)/(0.5*ΣMUFA+ 0.5*Σ(n-6 PUFA) + 3*Σ(n-3 PUFA)
+ (Σ(n-3 PUFA)/Σ(n-6 PUFA)), where ΣMUFA, Σ(n-6
PUFA), and Σ(n-3 PUFA) are the sum of MUFA, n-6 and
n-3 PUFA in wt % of total fatty acids, respectively.
Lipids and lipoproteins
Lipids were measured enzymatically in EDTA-plasma
on a Hitachi 917 system (Roche Diagnostics GmbH,
Mannheim, Germany) using the triacylglycerol (GPO-
PAP), cholesterol (CHOD-PAP), HDL-cholesterol plus
and LDL-cholesterol plus kit from Roche Diagnostics,
the non-esterified fatty acid (NEFA FS) kit and the
Phospholipids FS kit 17 from DiaSys Diagnostic Sys-
tems GmbH (Holzheim, Germany).
Lipoprotein size was measured in EDTA-plasma with
nuclear magnetic resonance (NMR) spectroscopy by
LabCorp Inc (Burlington, NC, USA), using the NMR
LipoProfile® test (http://www.labcorp.com).
Biochemical analysis
Plasma choline, betaine, trimethyllysine (TML), butyro-
betaine and trimethylamine N-oxide (TMAO), as well as
L-carnitine, acetylcarnitine, proponylcarnitine, octanoyl-
carnitine, iso-/L-valerylcarnitine and palmitoylcarnitine,
were analysed in EDTA-plasma using LC/MS/MS as
previously described [58, 59].
Clinical laboratory measurements, including safety pa-
rameters were measured in EDTA-plasma using routine
methods at the central laboratory at Haukeland Univer-
sity Hospital (Bergen, Norway).
Total AOC of plasma was measured using the total
antioxidant capacity kit (Abcam, Cambridge, UK) ac-
cording to the manufacturer’s instructions. The protein
mask was not used, enabling the analysis of both small
molecule antioxidants and proteins ability to reduce
Cu2+ to Cu+. In brief, EDTA-plasma was allowed to re-
duce Cu2+ for 1.5 hour at room temperature on an or-
bital shaker. The absorbance was measured at 570 nm
using a plate reader. Results were expressed as trolox
equivalents according to a trolox standard curve.
The levels of IL-1β, IL-10, IL-17, G-CSF and TNF-α
were measured in plasma samples using a custom-made
multiplex MILLIPLEX MAP kit (Millipore Corp., St.
Charles, IL, USA), and the assay solution was read by
the Bio-Plex array reader (Bio-Rad, Hercules, CA, USA)
and determined with the Bio-Plex Manager Software 4.1.
Questionnaires
All participants were asked to answer a questionnaire to
assess compliance, supplementation regime, product tol-
erance and to report of possible gastrointestinal (GI)
symptoms occurring when ingesting the supplement.
Compliance was further determined by capsule logs and
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validated by count of capsules in surplus. An authorised
clinical nutritionist interviewed the participants into the
regime, and general product tolerance.
Ethical aspects
All examinations and blood samples were performed at
the Department of Clinical Science, University of Bergen,
Norway. The study protocol was approved by the Regional
Ethics Committee of Northern Norway (Registration
number 2013/2152), and registered on ClinicalTrials.gov
(NCT02053415). All procedures were carried out in ac-
cordance with the ethical standards of the Helsinki declar-




Data sets were analysed using Prism Software (Prism
Graph-Pad Software, version 6, San Diego, California,
USA) to determine statistical significance. The results
are reported as means per group with their standard de-
viations (SD), with exception of age, BMI and compli-
ance, which is reported as mean with range. Wilcoxon
signed-rank test was performed to evaluate statistical
differences of matched pairs. Correlation coefficients (R)
were determined by Spearman correlation, and linear re-
gressions are shown in selected figures. P-values < 0.05
were considered significant.
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